Berkshire Hathaway said on Thursday night it sold 203,091 shares of DaVita , reducing its stake in the kidney dialysis services provider to about 35.89 million shares, a 45% stake worth nearly $6.4 billion.
DaVita HealthCare (DVA) came out with quarterly earnings of $2.24 per share, beating the Zacks Consensus Estimate of $2.21 per share. This compares to earnings of $1.87 per share a year ago.
Dialysis firm DaVita projected annual profit below estimates on Thursday due to rising patient care costs, sending its shares down 11% in after-hours trading.
Continued strength in RPT is likely to have boosted DaVita's top line in the fourth quarter despite supply challenges weighing on its performance.
The latest trading day saw DaVita HealthCare (DVA) settling at $177.35, representing a +0.16% change from its previous close.
Investors target stocks that have been on a bullish run lately. Stocks like ENS, DVA, REVG and PAA are seeing price strength and the momentum is likely to continue.
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $173.77, denoting a +0.32% change from the preceding trading day.
DaVita HealthCare (DVA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
DaVita HealthCare (DVA) closed at $169.90 in the latest trading session, marking a +0.86% move from the prior day.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare have been highlighted in this Industry Outlook article.